Tonix Pharmaceuticals Holding (TNXP) Common Equity (2023 - 2025)
Historic Common Equity for Tonix Pharmaceuticals Holding (TNXP) over the last 3 years, with Q3 2025 value amounting to $231.1 million.
- Tonix Pharmaceuticals Holding's Common Equity rose 21146.73% to $231.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $231.1 million, marking a year-over-year increase of 21146.73%. This contributed to the annual value of $139.6 million for FY2024, which is 3225.11% up from last year.
- Latest data reveals that Tonix Pharmaceuticals Holding reported Common Equity of $231.1 million as of Q3 2025, which was up 21146.73% from $168.0 million recorded in Q2 2025.
- Over the past 5 years, Tonix Pharmaceuticals Holding's Common Equity peaked at $231.1 million during Q3 2025, and registered a low of $42.1 million during Q2 2024.
- Its 3-year average for Common Equity is $134.2 million, with a median of $139.6 million in 2024.
- Per our database at Business Quant, Tonix Pharmaceuticals Holding's Common Equity plummeted by 7002.56% in 2024 and then soared by 29902.38% in 2025.
- Over the past 3 years, Tonix Pharmaceuticals Holding's Common Equity (Quarter) stood at $105.5 million in 2023, then skyrocketed by 32.25% to $139.6 million in 2024, then surged by 65.63% to $231.1 million in 2025.
- Its Common Equity stands at $231.1 million for Q3 2025, versus $168.0 million for Q2 2025 and $180.4 million for Q1 2025.